Stufenplanbeauftragter: Germany's national pharmacovigilance role, and how it leads to the EU QPPV

Germany writes a handful of pharma roles directly into law. If you work in drug safety anywhere in Europe, or you are an international professional targeting the German market, one of them matters to you more than the rest: the Stufenplanbeauftragter. The name does not translate gracefully, the literal rendering is something like graduated plan officer, and that may be why so little career guidance exists about it in English. Job ads assume you know it, authority guidance explains the duties, and the path into the seat goes undescribed.

This guide closes that gap, written from the perspective of 16 years recruiting in pharma, where named legal responsibility on a CV was reliably the line that separated senior profiles.

What the role actually owns

The duties sit in § 63a(1) AMG, and they are larger than the bureaucratic title suggests. The Stufenplanbeauftragter establishes and runs the company's pharmacovigilance system. They collect and assess reports of drug risks that come to the company's attention and coordinate the necessary measures. They own the company's notification duties toward the authorities, and when the competent authority asks, they provide the further information needed to assess a product's risk-benefit balance.

Translated into a working day: when a signal emerges, a cluster of adverse event reports, a quality defect with safety relevance, a new study finding, the threads converge on this person. They shape what goes to BfArM or the Paul-Ehrlich-Institut, on what timeline, with what assessment. It is a judgement role, not a documentation one, and in a crisis it is the seat that has to give management answers it would rather not hear.

The legal basis in brief: § 63a AMG

Three things from the statute are worth knowing before you aim at the seat. First, the duty to appoint: pharmaceutical entrepreneurs placing finished medicinal products on the German market must appoint a Stufenplanbeauftragter, with narrow exemptions under § 13(2) AMG. Second, the requirements on the person: the necessary expertise, the reliability required for the task, and residence in an EU member state, not necessarily Germany. Third, transparency toward the state: the appointment and every change are notified to the competent authority and the federal higher authority, immediately if the change is unforeseen.

Just as interesting is what the law does not say. No degree course, no minimum years, no certificate. The required expertise is an undefined legal term that the supervising authorities assess case by case. That makes the route more open than most people assume, and it makes practice weigh more than paper.

One more detail with career value: under § 63a(2), the Stufenplanbeauftragter may simultaneously act as the sachkundige Person (Qualified Person) under § 14 AMG or as the responsible person under § 20c. In mid-sized companies such combined mandates are common, and they are paid accordingly.

Stufenplanbeauftragter and EU QPPV: two roles, often one person

Europe has a sister role, the Qualified Person Responsible for Pharmacovigilance, the QPPV. It rests on Art. 104 of Directive 2001/83/EC and the EMA's GVP guidelines: every marketing authorisation holder must have permanently and continuously at its disposal an appropriately qualified person responsible for the pharmacovigilance system, residing and operating in the EU.

Germany layers the Stufenplanbeauftragter on top as an additional national appointment. For your career the practical reading is this: the two roles are related, not identical. At a German mid-sized company with EU authorisations, QPPV and Stufenplanbeauftragter frequently sit with the same person. At international groups, the EU QPPV usually sits in a global function while the Stufenplanbeauftragter holds the German interface. Anyone who has credibly filled the German seat carries almost everything the EU role demands. That makes it one of the few clearly describable ladders into one of the most sought-after senior positions in European drug safety.

The qualifications that actually count

Since the statute stays silent, what matters is the profile authorities and employers accept. The norm is a degree in pharmacy, medicine or a natural science, plus several years of hands-on pharmacovigilance: case processing and assessment, signal management, periodic safety reports, risk management plans, ideally inspection experience. If you are coming from clinical practice, a pharmacy or the lab, the realistic first step is an entry into drug safety; I have described those routes in the guide on getting into pharmacovigilance.

The second statutory requirement, reliability, gets underestimated. It points at personal integrity, and in hiring it translates into one question every employer quietly asks: will this person hold up in an inspection, and will they push back internally when it counts? Candidates who can tell a conflict story with substance, a signal they defended, a notification they forced through, come across stronger than any certificate list.

On language: communication with the German authorities runs in German, so for the national appointment solid German is the realistic expectation, with English a given at group and EMA level. For international profiles without German, the EU QPPV track is usually the more reachable target, and it hires in English.

The entry routes that work in practice

The most common route is internal: PV scientist or drug safety officer, then team responsibility, then deputyship, then the appointment. Many companies name a deputy who covers absences, and that deputy seat is the classic springboard. If you are offered it, take it, even without a pay rise. It is the evidence that matters later.

The second route runs through service providers. Specialised pharmacovigilance providers supply Stufenplanbeauftragte and QPPVs to companies that do not staff the function internally. There you accumulate experience across products, dosage forms and authority contacts at a pace a single company rarely offers. The third route is a senior-level switch from medical affairs or regulatory affairs with a strong safety footprint. It happens, but it is the rarest of the three.

What a CV has to evidence for this role

From a recruiter's chair, shortlists separate on evidence. A strong profile shows the chain from operational PV to accountability: case volumes and product classes handled, signal assessments with outcomes, PSUR and RMP ownership, inspection and audit history with your role in it, the common safety databases, authority correspondence. If you have held an appointment, whether as the named person or the deputy, write it explicitly, with dates. Employer ATS systems filter on exactly these terms; how to handle that is covered in the guide on the ATS in pharma.

The market across DACH

Demand is structural because the role is mandatory: originators, generics and biosimilar companies, biotechs approaching their first authorisation, plus a growing services market. Small companies want generalists who can carry several named functions; large companies want specialists who are inspection-proof. For experienced PV people the interim market adds another lane, because an unforeseen change must be notified to the authority without delay, and nobody leaves this seat empty for long. Austria and Switzerland run their own national requirements for pharmacovigilance responsibility, so if you think DACH-wide, check the target country separately.

A note on salary

I will not quote a band. Compensation depends on whether the appointment is combined with a leadership role or further named functions, whether it is held in-house or as an external mandate, and on the size and risk profile of the portfolio. A single number without those variables would mislead you. The direction is reliable: named responsibility under § 63a sits well above operational PV, and combining it with the EU QPPV moves the range further up.

Frequently asked questions

Does every pharma company in Germany need a Stufenplanbeauftragter?

Yes. Under § 63a AMG, every pharmaceutical entrepreneur placing finished medicinal products on the German market must appoint one, with narrow exemptions under § 13(2) AMG. Demand for the role is therefore structural: it exists at originators, generics companies and biotechs alike.

What is the difference between the Stufenplanbeauftragter and the EU QPPV?

The EU QPPV is the European role under Art. 104 of Directive 2001/83/EC and the GVP guidelines: one appropriately qualified person, permanently at the marketing authorisation holder's disposal, responsible for the pharmacovigilance system EU-wide, residing and operating in the EU. The Stufenplanbeauftragter is Germany's additional national appointment focused on the German market and German authorities. In German-centred companies both roles often sit with the same person; international groups usually separate them.

Do you need to live in Germany, or speak German, for the role?

The law requires residence in an EU member state, not in Germany. In practice, communication with the German authorities runs in German, so solid German is the realistic expectation for the national role. International professionals without German usually target the EU QPPV route instead, where English-language positions are common.

Can you hold the role as an external service provider?

Yes, and it is common. Many small and mid-sized companies appoint an external person through specialised pharmacovigilance providers or directly as a freelancer. For experienced PV professionals this is a career path of its own, running several mandates in parallel, but it presumes solid inspection and authority-facing experience.

Sources

§ 63a AMG, Stufenplanbeauftragter (gesetze-im-internet.de, German)
§ 13 AMG, manufacturing authorisation (gesetze-im-internet.de, German)
Directive 2001/83/EC, Art. 104 (EUR-Lex)
EMA: Pharmacovigilance / GVP guidelines
BfArM: Pharmacovigilance

© 27 July 2026 Andreas Schulz. All rights reserved. This article is career guidance, not legal advice; the statutory text prevails.